Sigma-Tau Pharmaceuticals To Conduct Phase II Clinical Trial In Europe With TB4 For Venous Stasis Ulcers; Pharmaceutical Firm Accelerates Phase II Commitment
10/19/2005 5:08:50 PM
RegeneRx Biopharmaceuticals, Inc. (OTCBB:RGRX) (www.regenerx.com) announced today that its strategic partner, Sigma-Tau Group (Sigma-Tau), is planning to conduct a Phase II clinical trial in Europe in the 4th quarter of 2004 to test Thymosin beta 4 (TB4) for the treatment of patients with venous stasis ulcers. The trial will be in addition to RegeneRx's planned Phase II trials in the U.S for the treatment of chronic pressure ulcers, epidermolysis bullosa, and other chronic dermal indications. In January 2004, RegeneRx exclusively licensed certain rights to TB4 to a wholly owned subsidiary within Sigma-Tau Group for the treatment of internal and external wound healing in Europe and other contiguous and geographically relevant countries.